Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:18473713rdf:typepubmed:Citationlld:pubmed
pubmed-article:18473713lifeskim:mentionsumls-concept:C1801960lld:lifeskim
pubmed-article:18473713lifeskim:mentionsumls-concept:C0311400lld:lifeskim
pubmed-article:18473713lifeskim:mentionsumls-concept:C0248719lld:lifeskim
pubmed-article:18473713lifeskim:mentionsumls-concept:C0231174lld:lifeskim
pubmed-article:18473713lifeskim:mentionsumls-concept:C0599894lld:lifeskim
pubmed-article:18473713pubmed:issue8lld:pubmed
pubmed-article:18473713pubmed:dateCreated2008-5-13lld:pubmed
pubmed-article:18473713pubmed:abstractTextAn angiotensin II type 1 receptor blocker (ARB), telmisartan, has the unique property of activation of PPAR-gamma.lld:pubmed
pubmed-article:18473713pubmed:languageenglld:pubmed
pubmed-article:18473713pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18473713pubmed:citationSubsetIMlld:pubmed
pubmed-article:18473713pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18473713pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18473713pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18473713pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18473713pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18473713pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18473713pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18473713pubmed:statusMEDLINElld:pubmed
pubmed-article:18473713pubmed:monthJunlld:pubmed
pubmed-article:18473713pubmed:issn1744-7666lld:pubmed
pubmed-article:18473713pubmed:authorpubmed-author:NodeKoichiKlld:pubmed
pubmed-article:18473713pubmed:authorpubmed-author:InoueTeruoTlld:pubmed
pubmed-article:18473713pubmed:issnTypeElectroniclld:pubmed
pubmed-article:18473713pubmed:volume9lld:pubmed
pubmed-article:18473713pubmed:ownerNLMlld:pubmed
pubmed-article:18473713pubmed:authorsCompleteYlld:pubmed
pubmed-article:18473713pubmed:pagination1397-406lld:pubmed
pubmed-article:18473713pubmed:meshHeadingpubmed-meshheading:18473713...lld:pubmed
pubmed-article:18473713pubmed:meshHeadingpubmed-meshheading:18473713...lld:pubmed
pubmed-article:18473713pubmed:meshHeadingpubmed-meshheading:18473713...lld:pubmed
pubmed-article:18473713pubmed:meshHeadingpubmed-meshheading:18473713...lld:pubmed
pubmed-article:18473713pubmed:meshHeadingpubmed-meshheading:18473713...lld:pubmed
pubmed-article:18473713pubmed:meshHeadingpubmed-meshheading:18473713...lld:pubmed
pubmed-article:18473713pubmed:meshHeadingpubmed-meshheading:18473713...lld:pubmed
pubmed-article:18473713pubmed:meshHeadingpubmed-meshheading:18473713...lld:pubmed
pubmed-article:18473713pubmed:meshHeadingpubmed-meshheading:18473713...lld:pubmed
pubmed-article:18473713pubmed:meshHeadingpubmed-meshheading:18473713...lld:pubmed
pubmed-article:18473713pubmed:meshHeadingpubmed-meshheading:18473713...lld:pubmed
pubmed-article:18473713pubmed:meshHeadingpubmed-meshheading:18473713...lld:pubmed
pubmed-article:18473713pubmed:year2008lld:pubmed
pubmed-article:18473713pubmed:articleTitleTelmisartan as a metabolic sartan for targeting vascular failure.lld:pubmed
pubmed-article:18473713pubmed:affiliationSaga University Faculty of Medicine, Department of Cardiovascular and Renal Medicine, 5-1-1 Nabeshima, Saga 849-8501, Japan. inouete@med.saga-u.ac.jplld:pubmed
pubmed-article:18473713pubmed:publicationTypeJournal Articlelld:pubmed